The deal also includes the potential for two additional net sales milestone payments of up to $350 million in aggregate if achieved before specific deadlines. "This announcement is fundamental progress on our Strategic Priority - Innovation," said Thomas J. Appio, Chief Executive Officer of Bausch Health. "It demonstrates our commitment to hepatology and finding new ways to address unmet medical needs." Alcoholic hepatitis is a life-threatening form of alcohol-associated liver disease that accounted for approximately 164,000 hospital admissions in the U.S. in 2021. There is currently no FDA or EMA approved treatment for the condition. The acquisition complements Bausch Health's ongoing Phase 3 program for rifaximin SSD being studied in cirrhotic patients globally. A registrational Phase 3 program to evaluate larsucosterol for treating severe AH is being planned as a randomized, double-blind, placebo-controlled, multi-center study with 90-day survival as the primary endpoint.